Invanz: profile and news
Merck Announces Strong Full-Year and Fourth-Quarter 2005 Earnings ... Jan 31, 2006
Merck announced in November that the FDA has approved INVANZ, a once-daily injectable antibiotic, for the treatment of moderate to severe complicated foot ... - TMCnet
Merck & Co. Gets Added Invanz FDA OK Nov 14, 2005
...said Monday that the Food and Drug Administration expanded marketing approval for its antibiotic Invanz to include diabetic foot infections. ... - MSN Money
FDA Approves New Indication for INVANZ(R) (ertapenem) for the ... Nov 14, 2005
...announced today that the US Food and Drug Administration (FDA) has approved INVANZ(R) (ertapenem), a once-daily injectable antibiotic, for the treatment of ... - Business Wire (press release),
FDA Approvals: Exjade, Oncaspar, Invanz Nov 17, 2005
14, the FDA approved a new indication for once-daily ertapenem injection (Invanz, made by Merck & Co., Inc.), allowing its use for the treatment of moderate to ... - Medscape (subscription)
Once-Daily IV Antibiotic Effective for Diabetic Foot Infections Nov 10, 2005
11 - Invanz (ertapenem) is as effective as Zosyn (piperacillin/tazobactam) for diabetic foot infections but has the convenience of once-daily dosing, according ... - MedPage Today,
FDA OKs new use for Merck antibiotic Nov 14, 2005
WASHINGTON, Nov. 14 (UPI) -- The Food and Drug Administration has approved a new use for Merck's injectable antibiotic Invanz to treat diabetic foot infection. ... - United Press International
FDA OKs new use for Merck antibiotic Nov 14, 2005
Inc. with approval of a new use for Merck's injectable antibiotic Invanz. ... Invanz belongs to a class of antibiotics known as beta-lactams. ... - Webindia123,
Merck Announces Initial Steps In Global Restructuring Program Nov 28, 2005
...reported products* $5.9 to $6.2 billion * Other reported products comprise: AGGRASTAT, ARCOXIA, CANCIDAS, COSOPT, CRIXIVAN, EMEND, INVANZ, MAXALT, PRIMAXIN ... - Business Wire (press release),
Merck antibiotic also approved for foot infection Nov 14, 2005
Inc. said on Monday that regulators will allow it to sell its injectable antibiotic Invanz as a treatment for foot infections associated with diabetes. ... - Reuters.uk,
Merck antibiotic also approved for foot infection Nov 14, 2005
14 (Reuters) -- Merck & Co. Inc. (MRK.N: Quote, Profile, Research) said on Monday that regulators will allow it to sell its injectible antibiotic Invanz as a ... - Reuters
Cherokee operation to be sold by Merck Nov 30, 2005
Humphrey said. The plant makes pharmaceutical ingredients for several antibiotics, including Invanz, Primaxin and Elspar. Ed Vallo ... - Patriot-News,
Merck Announces New Unisured Discount Program Targeted to More ... Oct 7, 2005
...medicines, including CANCIDAS(R) (caspofungin acetate) for Injection, CRIXIVAN(R) (indinavir sulfate) Capsules, and EMEND(R) (aprepitant), INVANZ(R) (ertapenem ... - Hispanic PR Wire (press release),
Merck to invest $15 mn to beef up marketing Sep 27, 2005
The new products of MSD Pharma to be introduced in the country include Invanz, an anti-biotic, Cancidas, an anti-fungal and two vaccines, Pneumovax anti ... - Business Standard,
Merck re-enters India; product launches in pipeline Jul 22, 2005
The products include Invanz, a second generation beta-lactam anti-biotic, Cancidas, an anti-fungal and two vaccines, Pneumovax (anti-pneumonia) and Varivax ... - Hindu
Merck re-enters Indian market Jul 22, 2005
This will be followed by the launch of Invanz (a second generation beta-lactam anti-biotic) and Cancidas (an anti-fungal) and two vaccines — Pneumovax (anti ... - Hindu
Merck re-enters India with $15 mn investment:- Jul 22, 2005
The four drugs are: Invanz (an antibiotic used to treat gram positive and negative bacteria), Cancidas (anti-fungal drug), Pneumovax (pneumonia vaccine) and ... - Webindia123
Merck Announces Second-Quarter 2005 Earnings Per Share (EPS) of 33 ... Jul 21, 2005
Other reported products* $5.9 to $6.2 billion *Other reported products comprise: AGGRASTAT, ARCOXIA, CANCIDAS, COSOPT, CRIXIVAN, EMEND, INVANZ, MAXALT, PRIMAXIN ... - Business Wire (press release)
Merck Announces First-Quarter 2005 Earnings Per Share -EPS- of 62 ... Apr 21, 2005
...reported products* $5.9 to $6.2 billion * Other reported products comprise: AGGRASTAT, ARCOXIA, CANCIDAS, COSOPT, CRIXIVAN, EMEND, INVANZ, MAXALT, PRIMAXIN ... - Business Wire
Merck Announces New Unisured Discount Program Targeted to More ... Apr 19, 2005
...medicines, including CANCIDAS(R) (caspofungin acetate) for Injection, CRIXIVAN(R) (indinavir sulfate) Capsules, and EMEND(R) (aprepitant), INVANZ(R) (ertapenem ... - Hispanic PR Wire
Governor Tom Vilsack Supports New Merck Uninsured Discount Program ... Apr 20, 2005
...medicines, including CANCIDAS(R) (caspofungin acetate) for Injection, CRIXIVAN(R) (indinavir sulfate) Capsules, EMEND(R) (aprepitant), INVANZ(R) (ertapenem for ... - PR Newswire
